Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 90 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

10%

4 of 42 completed trials have results

Key Signals

22 recruiting4 with results

Enrollment Performance

Analytics

N/A
51(68.9%)
Phase 2
18(24.3%)
Phase 1
5(6.8%)
74Total
N/A(51)
Phase 2(18)
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (90)

Showing 20 of 90 trials
NCT07540650Phase 2Not Yet Recruiting

Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers

Role: lead

NCT04281290Not ApplicableActive Not Recruiting

Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)

Role: collaborator

NCT07466472Not Yet Recruiting

Image-Guided Central Catheter Insertion With Concurrent Assessment of Vascular Wall Integrity

Role: collaborator

NCT07457255Not ApplicableCompleted

Late Endocrine and Metabolic Consequences After Childhood Brain Tumor Treatment

Role: lead

NCT07432399Phase 2Recruiting

Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)

Role: lead

NCT06650423Recruiting

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Role: lead

NCT07427953Completed

Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma

Role: lead

NCT07432308Not ApplicableCompleted

Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC

Role: lead

NCT07431684Not ApplicableActive Not Recruiting

Sense of Coherence and Quality of Life in Prostate Cancer Patients Treated With Radical Radiotherapy

Role: lead

NCT07447544Not ApplicableActive Not Recruiting

Predictive Factors for CNS Metastases in Early Breast Cancer Using Liquid Biopsy (AKRA CŽS)

Role: lead

NCT07431645Phase 1Completed

Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells

Role: lead

NCT07443514Not ApplicableRecruiting

Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma

Role: lead

NCT07443475Phase 2Recruiting

Electrochemotherapy for Recurrent Vulvar Cancer

Role: lead

NCT07436390Not ApplicableCompleted

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Role: lead

NCT07436416Not ApplicableCompleted

Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer

Role: lead

NCT07439328Not ApplicableCompleted

ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer

Role: lead

NCT07428252Not ApplicableActive Not Recruiting

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

Role: lead

NCT07416500Not ApplicableCompleted

BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential

Role: lead

NCT07431489Not ApplicableCompleted

Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors

Role: lead

NCT07428733Not ApplicableCompleted

Gene Methylation for Diagnosis of Breast Lesions

Role: lead